Executive Director, Total Rewards

Executive Director, Total Rewards Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting, and continue to advance an early-stage pipeline of novel therapeutic candidates. In 2025, we initiated Phase 1 trials for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7). Nav1.7 and Kv7 are important pain targets, and data from these Phase 1 studies are expected in 2026 to support Phase 2 proof-of-concept studies in acute pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. About the Role: We are seeking an Executive Director, Total Rewards to join our team. The Executive Director, Total Rewards will be a key member of a highly collaborative HR team and will evolve, develop, and manage the execution of total compensation strategies and programs to align with near- and long-term business objectives, our culture and values, and are market competitive to enable Xenon to attract, reward, and retain top talent in the U.S. and Canada. The Executive Director, Total Rewards will be a strategic thinker who is also highly hands-on and enjoys getting into the details to ensure our programs have well-articulated principles and design, robust end-to-end processes, and flawless execution. The Executive Director, Total Rewards will propose and lead benefits program design in the US and depending on qualifications and experience, Canada. In addition, the successful candidate will have proven leadership ability in a fast-paced, multi-jurisdiction environment and will interact with all levels of internal staff, as well as external advisors and suppliers. This is a hands-on role with plans to grow a team in accordance with business need. The Executive Director, Total Rewards will work closely with a broad range of internal and external partners, including organization leaders, HR Business Partners (HRBPs), Finance and Legal colleagues and external compensation advisors and suppliers. In collaboration with other key functions, the position will ensure compliance with legal and regulatory requirements in the U.S. and Canada as relates to compensation. This position reports to the Executive Vice President, Human Resources and will be based out of Vancouver, BC, Canada or Boston, MA, ... (truncated, view full listing at source)